Clinical and morphological characteristics IgG4-associated retroperitoneal fibrosis

Cover Page

Cite item

Abstract

Background: Retroperitoneal fibrosis (RF) is a rare disease with inflammation and fibrosis of the retroperitoneal soft tissues and adjacent organ involvement. At present, a proportion of RF cases are believed to be IgG4-associated. Aim: Clinical and morphological comparison of the IgG4-associated and idiopathic (non-IgG-associated) RF. Materials and methods: The study was based on a comprehensive morphological assessment of surgical and biopsy samples taken from 12 RF patients. In addition to hematoxylin eosin stained specimens, we performed immunohistochemistry (IHC) with determination of absolute CD138+ counts, IgG+ and IgG4+ cells in the inflammatory infiltration, as well as IgG4/IgG and IgG4+/CD138+ ratios. Results: The proportion the IgG4-associated RF was 66.7% (8/12). The majority of IgG4-associated RF patients were men, with the mean age of 54.9 ± 10.3 years. Idiopathic RF was found without any gender imbalance in the younger patients. In all cases of IgG4-associated RF, the adjacent organs were also involved, whereas in those with idiopathic RF the aortic wall was involved in only half of the cases. Morphological specimen investigation in IgG4-associated RF showed signs characteristic for an IgG4-associated disorder, such as advanced lymphoplasmocytic infiltration, storiform fibrosis, and obliterating phlebitis. IgG4+ plasma cells numbers in the infiltrates was at least 25 per high-power field, and the IgG4+/IgG+ and IgG4+/CD138+ ratios exceeded 50% in all cases. No signs of an IgG4-associated disease were found in idiopathic RF, with significantly lower numbers of IgG+ and IgG4+ plasma cells in the infiltrations and the IgG4+/IgG+ ratio below 10%. Conclusion: A big proportion of RF is IgG4-associated, being an intrinsic feature of a systemic autoimmune IgG4-associated disease. The differential diagnosis should be based on the morphological assessment and immunohistochemistry results with obligatory identification of CD138, IgG, and IgG4 expression in the involved tissues. In some cases, it allows for avoidance of an unnecessary surgery. Reliable and accurate diagnosis would determine the subsequent treatment strategy of these patients.

About the authors

S. V. Lishchuk

State Research Center – Burnasyan Federal Medical Biophysical Center

Author for correspondence.
Email: slishuk@fmbcfmba.ru
ORCID iD: 0000-0003-0372-5886

Sergey V. Lishchuk - MD, PhD, Head of Department of Pathology.

46 Zhivopisnaya ul., Moscow, 123182.

Tel.: +7 (499) 190 94 90.

Russian Federation

E. A. Dubova

State Research Center – Burnasyan Federal Medical Biophysical Center

Email: fake@neicon.ru
ORCID iD: 0000-0002-7115-538X

Elena A. Dubova - MD, PhD, Pathologist.

46 Zhivopisnaya ul., Moscow, 123182.

Russian Federation

K. A. Pavlov

State Research Center – Burnasyan Federal Medical Biophysical Center

Email: fake@neicon.ru
ORCID iD: 0000-0002-9076-8907

Konstantin A. Pavlov - MD, PhD, Pathologist.

46 Zhivopisnaya ul., Moscow, 123182.

Russian Federation

A. M. Borbat

State Research Center – Burnasyan Federal Medical Biophysical Center

Email: fake@neicon.ru
ORCID iD: 0000-0002-9699-8375

Artyom M. Borbat - MD, PhD, Pathologist.

46 Zhivopisnaya ul., Moscow, 123182.

Russian Federation

Yu. D. Udalov

State Research Center – Burnasyan Federal Medical Biophysical Center

Email: fake@neicon.ru
ORCID iD: 0000-0002-9739-8478

Yury D. Udalov - MD, PhD, Head Physician.

46 Zhivopisnaya ul., Moscow, 123182.

Russian Federation

References

  1. Lian L, Wang C, Tian JL. IgG4-related retroperitoneal fibrosis: a newly characterized disease. Int J Rheum Dis. 2016;19(11):1049-55. doi: 10.1111/1756-185X.12863.
  2. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241-51. doi: 10.1016/S0140-6736(06)68035-5.
  3. Казанцева ИА, Лищук СВ. Новая системная патология - 1с^4-связанная склерозирующая болезнь. Клиническая и экспериментальная морфология. 2013;(2):12-7.
  4. Пальцева ЕМ, Должанский ОВ, Морозова ММ, Лищук СВ, Степаненко АБ, Чарчян ЭР, Федоров ДН. IgG4-связанный хронический периаортит с ретроперитонеальным фиброзом. Архив патологии. 2014;76(2):32-5.
  5. Fujimori N, Ito T, Igarashi H, Oono T, Nakamura T, Niina Y, Hijioka M, Lee L, Uchida M, Takayanagi R. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease. World J Gastroenterol. 2013;19(1):35-41. doi: 10.3748/wjg.v19.i1.35.
  6. Urban ML, Palmisano A, Nicastro M, Corradi D, Buzio C, Vaglio A. Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach. Rev Med Interne. 2015;36(1):15-21. doi: 10.1016/j.revmed.2014.10.008.
  7. Tzou M, Gazeley DJ, Mason PJ. Retroperitoneal fibrosis. Vasc Med. 2014;19(5):407-14. doi: 10.1177/1358863X14546160.
  8. Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med. 2017;12(3):287-99. doi: 10.1007/s11739-016-1599-z.
  9. Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol. 2010;34(12):1812-9. doi: 10.1097/PAS.0b013e3181f7266b.
  10. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Kloppel G, Heathcote JG, Khosroshahi A, Ferry JA, Aalberse RC, Bloch DB, Brugge WR, Bateman AC, Carruthers MN, Chari ST, Cheuk W, Cornell LD, Fernandez-Del Castillo C, Forcione DG, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Lauwers GY, Masaki Y, Nakanuma Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani DV, Smyrk TC, Stone JR, Takahira M, Webster GJ, Yamamoto M, Zamboni G, Umehara H, Stone JH. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-92. doi: 10.1038/mod-pathol.2012.72.
  11. Uibu T, Oksa P, Auvinen A, Honkanen E, Metsarinne K, Saha H, Uitti J, Roto P. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet. 2004;363(9419):1422-6. doi: 10.1016/S0140-6736(04)16100-X.
  12. van Bommel EF, Jansen I, Hendriksz TR, Aar-noudse AL. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). 2009;88(4):193-201. doi: 10.1097/MD.0b013e3181afc420.
  13. Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, Deshpande V. Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). 2013;92(2):82-91. doi: 10.1097/MD.0b013e318289610f.
  14. Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, Namiki M, Kasashima S, Kawashima A, Matsumoto Y, Katayanagi K, Murata T, Ishizawa S, Hosaka N, Kuriki K, Nakanuma Y. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33(12):1833-9. doi: 10.1097/pas.0b013e3181b72882.
  15. Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-re-lated systemic disease. Curr Opin Rheumatol. 2011;23(1):88-94. doi: 10.1097/BOR.0b013e-3283412f7c.
  16. Lin W, Lu S, Chen H, Wu Q, Fei Y, Li M, Zhang X, Tian X, Zheng W, Leng X, Xu D, Wang Q, Shen M, Wang L, Li J, Wu D, Zhao L, Wu C, Yang Y, Peng L, Zhou J, Wang Y, Sha Y, Huang X, Jiao Y, Zeng X, Shi Q, Li P, Zhang S, Hu C, Deng C, Li Y, Zhang S, Liu J, Su J, Hou Y, Jiang Y, You X, Zhang H, Yan L, Zhang W, Zhao Y, Zeng X, Zhang F, Lipsky PE. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford). 2015;54(11):1982-90. doi: 10.1093/rheumatology/kev203.
  17. Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, Kulikova M, Deshpande V, Pillai S, Stone JH. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190-5. doi: 10.1136/annrheumdis-2014-205233.
  18. Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, Deshpande V, Stone JH, Pillai S. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014;134(3):679-87. doi: 10.1016/j.jaci.2014.03.034.
  19. Khosroshahi A, Wallace ZS, Crowe JL, Akam-izu T, Azumi A, Carruthers MN, Chari ST, Della-Torre E, Frulloni L, Goto H, Hart PA, Kamisawa T, Kawa S, Kawano M, Kim MH, Kodama Y, Kubota K, Lerch MM, Lohr M, Masaki Y, Matsui S, Mimori T, Nakamura S, Nakazawa T, Ohara H, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Shimatsu A, Shimosegawa T, Takahashi H, Takahira M, Tanaka A, Topazian M, Umehara H, Webster GJ, Witzig TE, Yamamoto M, Zhang W, Chiba T, Stone JH; Second International Symposium on IgG4-Related Disease. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol. 2015;67(7):1688-99. doi: 10.1002/art.39132.
  20. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2020 Lishchuk S.V., Dubova E.A., Pavlov K.A., Borbat A.M., Udalov Y.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies